December 29, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Anavex Life Sciences Corporation (“Anavex” or the “Company”) (Nasdaq: AVXL) for potential violations of the federal securities laws. Investors who purchased Company securities between October 25, 2015 and December 28, 2015 may be affected.
On October 28, 2015, Anavex began trading its common stock on the Nasdaq Capital market at the opening of market hours under the symbol “AVXL.”
On December 29, 2015, before the opening of the market, the Company filed with the SEC its annual report for the fiscal year ended September 30, 2015 on Form 10-K. The Company’s 2015 10-K disclosed that on December 22, 2015, the Company “received a subpoena from the Securities and Exchange Commission (SEC) which indicates that the agency is conducting a formal investigation. The Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares. The Company is fully cooperating with the SEC in this investigation and is unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it.”
By mid-trading day on December 29, 2015, the Company’s shares declined $0.85 per share or approximately 12%.
If you purchased Anavex securities and would like to discuss our investigation, please contact us by e-mailing
or by calling 800-290-1952.
Attorneys: Laurence D. King, Jeffrey P. Campisi